Surmodics Balance Sheet Health
Financial Health criteria checks 3/6
Surmodics has a total shareholder equity of $118.9M and total debt of $29.6M, which brings its debt-to-equity ratio to 24.9%. Its total assets and total liabilities are $178.6M and $59.7M respectively.
Key information
24.9%
Debt to equity ratio
US$29.55m
Debt
| Interest coverage ratio | n/a |
| Cash | US$40.11m |
| Equity | US$118.90m |
| Total liabilities | US$59.67m |
| Total assets | US$178.56m |
Recent financial health updates
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17
Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Recent updates
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Jun 06Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 30Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Financial Position Analysis
Short Term Liabilities: SRDX's short term assets ($81.3M) exceed its short term liabilities ($20.5M).
Long Term Liabilities: SRDX's short term assets ($81.3M) exceed its long term liabilities ($39.1M).
Debt to Equity History and Analysis
Debt Level: SRDX has more cash than its total debt.
Reducing Debt: SRDX's debt to equity ratio has increased from 0% to 24.9% over the past 5 years.
Debt Coverage: SRDX's debt is not well covered by operating cash flow (0.8%).
Interest Coverage: Insufficient data to determine if SRDX's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:08 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Daniel Owczarski | Avondale Partners |
| Michael Petusky | Barrington Research Associates, Inc. |